BMS-707035

BMS‑707035 is a potent, orally active small molecule inhibitor of HIV‑1 integrase strand transfer (INSTI), developed by Bristol Myers Squibb for the treatment of HIV infection. It acts by specifically and reversibly blocking the activity of the HIV integrase enzyme, thereby preventing integration of viral DNA into the host genome—a critical step in viral replication. The compound was discovered through systematic optimization of N-methylpyrimidinone carboxamides and advanced to phase I/II clinical trials based on its strong antiviral activity and favorable preclinical profile. However, development was discontinued before approval[5][3][6][2].

Other names

HIV Integrase InhibitorUNII-7PR4P7YOKTUNII7PR4P7YOKTUNII 7PR4P7YOKT2-(1,1-dioxido-1,2-thiazinan-2-yl)-N-(4-fluorobenzyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide